减肥手术和GLP-1/GIP药物治疗阻塞性睡眠呼吸暂停:综合综述

IF 11 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Amr Alnagar, Yashashwi Sinha, Adil N Ahmad, Awais Ahmed, Mohamed Saleem Noormohamed
{"title":"减肥手术和GLP-1/GIP药物治疗阻塞性睡眠呼吸暂停:综合综述","authors":"Amr Alnagar, Yashashwi Sinha, Adil N Ahmad, Awais Ahmed, Mohamed Saleem Noormohamed","doi":"10.1007/s13679-025-00640-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review evaluates the comparative efficacy of bariatric surgery and pharmacological interventions targeting Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors. Recent advancements, including the FDA approval of Tirzepatide (Zepbound) for OSA, are critically analysed alongside existing literature, offering insights into physiological mechanisms, long-term outcomes, and patient selection criteria.</p><p><strong>Recent findings: </strong>OSA is a chronic condition characterized by repetitive upper airway collapse during sleep, resulting in intermittent hypoxia and sleep fragmentation. With obesity being a primary risk factor, weight management has emerged as a key intervention in OSA treatment. Direct comparisons of bariatric surgery and GLP-1/GIP receptor agonists in treating OSA are limited due to a lack of randomised controlled trials. Observational studies suggest that bariatric surgery typically results in faster and more sustained weight loss, leading to better initial OSA improvement. In contrast, pharmacotherapy offers a non-invasive option for patients who cannot undergo surgery. Randomized trials comparing these treatment modalities are essential to refine treatment algorithms and enhance patient care. A multidisciplinary, patient-centered approach is crucial for ensuring long-term success and improving the quality of life for individuals with obesity-related OSA.</p>","PeriodicalId":10846,"journal":{"name":"Current Obesity Reports","volume":"14 1","pages":"48"},"PeriodicalIF":11.0000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bariatric Surgery and GLP-1/GIP Medications for the Treatment of Obstructive Sleep Apnoea: A Comprehensive Review.\",\"authors\":\"Amr Alnagar, Yashashwi Sinha, Adil N Ahmad, Awais Ahmed, Mohamed Saleem Noormohamed\",\"doi\":\"10.1007/s13679-025-00640-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>This review evaluates the comparative efficacy of bariatric surgery and pharmacological interventions targeting Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors. Recent advancements, including the FDA approval of Tirzepatide (Zepbound) for OSA, are critically analysed alongside existing literature, offering insights into physiological mechanisms, long-term outcomes, and patient selection criteria.</p><p><strong>Recent findings: </strong>OSA is a chronic condition characterized by repetitive upper airway collapse during sleep, resulting in intermittent hypoxia and sleep fragmentation. With obesity being a primary risk factor, weight management has emerged as a key intervention in OSA treatment. Direct comparisons of bariatric surgery and GLP-1/GIP receptor agonists in treating OSA are limited due to a lack of randomised controlled trials. Observational studies suggest that bariatric surgery typically results in faster and more sustained weight loss, leading to better initial OSA improvement. In contrast, pharmacotherapy offers a non-invasive option for patients who cannot undergo surgery. Randomized trials comparing these treatment modalities are essential to refine treatment algorithms and enhance patient care. A multidisciplinary, patient-centered approach is crucial for ensuring long-term success and improving the quality of life for individuals with obesity-related OSA.</p>\",\"PeriodicalId\":10846,\"journal\":{\"name\":\"Current Obesity Reports\",\"volume\":\"14 1\",\"pages\":\"48\"},\"PeriodicalIF\":11.0000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Obesity Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13679-025-00640-0\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Obesity Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13679-025-00640-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

综述目的:本综述评估了针对胰高血糖素样肽-1 (GLP-1)和葡萄糖依赖性胰岛素多肽(GIP)受体的减肥手术和药物干预的比较疗效。最近的进展,包括FDA批准tizepatide (Zepbound)治疗OSA,与现有文献一起进行了批判性分析,提供了对生理机制,长期结果和患者选择标准的见解。最近发现:OSA是一种慢性疾病,其特征是睡眠中反复出现上呼吸道塌陷,导致间歇性缺氧和睡眠破碎。由于肥胖是主要的危险因素,体重管理已成为OSA治疗的关键干预措施。由于缺乏随机对照试验,对减肥手术和GLP-1/GIP受体激动剂治疗OSA的直接比较受到限制。观察性研究表明,减肥手术通常能更快、更持久地减轻体重,从而更好地改善最初的OSA。相比之下,药物治疗为不能接受手术的患者提供了一种非侵入性的选择。比较这些治疗方式的随机试验对于完善治疗算法和加强患者护理至关重要。多学科、以患者为中心的方法对于确保肥胖相关OSA患者的长期成功和改善其生活质量至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Bariatric Surgery and GLP-1/GIP Medications for the Treatment of Obstructive Sleep Apnoea: A Comprehensive Review.

Purpose of review: This review evaluates the comparative efficacy of bariatric surgery and pharmacological interventions targeting Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors. Recent advancements, including the FDA approval of Tirzepatide (Zepbound) for OSA, are critically analysed alongside existing literature, offering insights into physiological mechanisms, long-term outcomes, and patient selection criteria.

Recent findings: OSA is a chronic condition characterized by repetitive upper airway collapse during sleep, resulting in intermittent hypoxia and sleep fragmentation. With obesity being a primary risk factor, weight management has emerged as a key intervention in OSA treatment. Direct comparisons of bariatric surgery and GLP-1/GIP receptor agonists in treating OSA are limited due to a lack of randomised controlled trials. Observational studies suggest that bariatric surgery typically results in faster and more sustained weight loss, leading to better initial OSA improvement. In contrast, pharmacotherapy offers a non-invasive option for patients who cannot undergo surgery. Randomized trials comparing these treatment modalities are essential to refine treatment algorithms and enhance patient care. A multidisciplinary, patient-centered approach is crucial for ensuring long-term success and improving the quality of life for individuals with obesity-related OSA.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Obesity Reports
Current Obesity Reports Medicine-General Medicine
CiteScore
16.40
自引率
1.10%
发文量
25
期刊介绍: The main objective of Current Obesity Reports is to provide expert review articles on recent advancements in the interdisciplinary field of obesity research. Our aim is to offer clear, insightful, and balanced contributions that will benefit all individuals involved in the treatment and prevention of obesity, as well as related conditions such as cardiovascular diseases, endocrine disorders, gynecological issues, cancer, mental health, respiratory complications, and rheumatological diseases. We strive to redefine the way knowledge is expressed and provide organized content for the benefit of our readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信